Voya Investment Management LLC Sells 13,358 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Voya Investment Management LLC trimmed its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 16.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 70,347 shares of the medical equipment provider's stock after selling 13,358 shares during the quarter. Voya Investment Management LLC's holdings in Zimmer Biomet were worth $7,431,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Roman Butler Fullerton & Co. acquired a new stake in shares of Zimmer Biomet during the 4th quarter worth approximately $473,000. KLCM Advisors Inc. acquired a new stake in Zimmer Biomet in the fourth quarter worth $7,825,000. Peddock Capital Advisors LLC acquired a new position in shares of Zimmer Biomet during the fourth quarter valued at about $654,000. Van ECK Associates Corp boosted its position in shares of Zimmer Biomet by 5.9% during the 4th quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider's stock worth $417,814,000 after purchasing an additional 218,688 shares in the last quarter. Finally, Reinhart Partners LLC. boosted its position in shares of Zimmer Biomet by 34.4% during the 4th quarter. Reinhart Partners LLC. now owns 86,755 shares of the medical equipment provider's stock worth $9,164,000 after purchasing an additional 22,220 shares in the last quarter. Institutional investors own 88.89% of the company's stock.

Insider Activity at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares of the company's stock, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.95% of the stock is currently owned by corporate insiders.

Zimmer Biomet Stock Performance

Zimmer Biomet stock traded up $0.26 during trading on Friday, hitting $102.08. The stock had a trading volume of 3,275,103 shares, compared to its average volume of 1,662,422. The stock's 50 day moving average is $105.53 and its two-hundred day moving average is $106.52. Zimmer Biomet Holdings, Inc. has a 1 year low of $93.10 and a 1 year high of $122.25. The stock has a market cap of $20.20 billion, a price-to-earnings ratio of 22.94, a price-to-earnings-growth ratio of 1.95 and a beta of 0.78. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the prior year, the business posted $2.20 earnings per share. As a group, analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, April 30th. Investors of record on Monday, March 31st were paid a $0.24 dividend. The ex-dividend date was Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 0.94%. Zimmer Biomet's dividend payout ratio is 21.57%.

Analysts Set New Price Targets

Several brokerages have issued reports on ZBH. JMP Securities reiterated a "market outperform" rating and issued a $140.00 price target on shares of Zimmer Biomet in a report on Friday, February 7th. Needham & Company LLC restated a "hold" rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Raymond James lowered their price objective on shares of Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. Truist Financial reiterated a "hold" rating and set a $113.00 price objective (down from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Finally, BTIG Research reaffirmed a "buy" rating on shares of Zimmer Biomet in a research report on Monday, April 14th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.